p.93 抽出テキスト

Kusumoto et al 2018 Bradycardia Clinical Practice Guidelines

August 20, 2019 Circulation. 2019;140:e382–e482. DOI: 10.1161/CIR.0000000000000628 e474

CLINICAL STATEMENTS AND GUIDELINES S8.1.2.4-7.	 Roten L, Wenaweser P, Delacretaz E, et al. Incidence and predic-

tors of atrioventricular conduction impairment after transcatheter aortic valve implantation. Am J Cardiol. 2010;106:1473–80. S8.1.2.4-8.	 Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60–9. S8.1.2.4-9.	 Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloonexpandable valve. J Am Coll Cardiol. 2012;60:1743–52. S8.1.2.4-10.	 Testa L, Latib A, De Marco F, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValve Revalving System. Circulation. 2013;127:1300–7. S8.1.2.4-11.	 Franzoni I, Latib A, Maisano F, et al. Comparison of incidence and predictors of left bundle branch block after transcatheter aortic valve implantation using the CoreValve versus the Edwards valve. Am J Cardiol. 2013;112:554–9. S8.1.2.4-12.	 Toggweiler S, Stortecky S, Holy E, et al. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring. JACC Cardiovasc Interv. 2016;9:1269–76. S8.1.2.4-13.	 van der Boon RM, Van Mieghem NM, Theuns DA, et al. Pacemaker dependency after transcatheter aortic valve implantation with the self-expanding Medtronic CoreValve System. Int J Cardiol. 2013;168:1269–73. S8.1.2.4-14.	 Dizon JM, Nazif TM, Hess PL, et al. Chronic pacing and adverse outcomes after transcatheter aortic valve implantation. Heart. 2015;101:1665–71. S8.1.2.4-15.	 Mauri V, Reimann A, Stern D, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv. 2016;9: 2200–9. S8.1.2.4-16.	 Schymik G, Tzamalis P, Bramlage P, et al. Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the TAVIK cohort. Clin Res Cardiol. 2015;104:351–62. S8.1.2.4-17.	 Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol. 2015;65:437–48. S8.1.2.4-18.	 Nazif TM, Williams MR, Hahn RT, et al. Clinical implications of new-onset left bundle branch block after transcatheter aortic valve replacement: analysis of the PARTNER experience. Eur Heart J. 2014;35:1599–607. S8.1.2.4-19.	 Auffret V, Webb JG, Eltchaninoff H, et al. Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:1564–74. S8.1.2.4-20.	 Rampat R, Khawaja MZ, Hilling-Smith R, et al. Conduction abnormalities and permanent pacemaker implantation after transcatheter aortic valve replacement using the repositionable LO- TUS device: the United Kingdom experience. JACC Cardiovasc Interv. 2017;10:1247–53. S8.1.2.4-21.	 Rivard L, Schram G, Asgar A, et al. Electrocardiographic and elec-

trophysiological predictors of atrioventricular block after transcatheter aortic valve replacement. Heart Rhythm. 2015;12:321–9.

8.1.2.5 Heart Transplant, Surgical Myectomy, and Alcohol Septal Ablation

8.1.2.5.1 After Heart Transplant

S8.1.2.5.1-1.	 Cantillon DJ, Tarakji KG, Hu T, et al. Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm. 2010;7:1567–71. S8.1.2.5.1-2.	 Jones DG, Mortsell DH, Rajaruthnam D, et al. Permanent pacemaker implantation early and late after heart transplantation: clinical indication, risk factors and prognostic implications. J Heart Lung Transplant. 2011;30:1257–65. S8.1.2.5.1-3.	 Mallidi HR, Bates M. Pacemaker use following heart transplan-

tation. Ochsner J. 2017;17:20–4. S8.1.2.5.1-4.	 Wellmann P, Herrmann FE, Hagl C, et al. A single center study

of 1 179 heart transplant patients—factors affecting pacemaker implantation. Pacing Clin Electrophysiol. 2017;40:247–54. S8.1.2.5.1-5.	 Knight CS, Tallaj JA, Rayburn BK, et al. Bradycardia and syn-

cope as a presentation of cardiac allograft rejection involving the conducting system. Cardiovasc Pathol. 2010;19:117–20.

8.1.2.5.2 Surgical Myectomy and Alcohol Septal Ablation for Hypertrophic Cardiomyopathy

S8.1.2.5.2-1.	 Axelsson A, Weibring K, Havndrup O, et al. Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2014;15:214–21. S8.1.2.5.2-2.	 El-Jack SS, Nasif M, Blake JW, et al. Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20:73–6. S8.1.2.5.2-3.	 Liebregts M, Faber L, Jensen MK, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10:1134– 43. S8.1.2.5.2-4.	 Veselka J, Lawrenz T, Stellbrink C, et al. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2013;29:1415–21. S8.1.2.5.2-5.	 Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–12. S8.1.2.5.2-6.	 Thavikulwat AC, Tomson TT, Knight BP, et al. Appropriate implantable defibrillator therapy in adults with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27:953–60. S8.1.2.5.2-7.	 Wang W, Lian Z, Rowin EJ, et al. Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 10;2017:e004604. S8.1.2.5.2-8.	 Balt JC, Wijffels MC, Boersma LV, et al. Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic cardiomyopathy. Heart. 2014;100:1865–70. S8.1.2.5.2-9.	 Lawrenz T, Lieder F, Bartelsmeier M, et al. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:2356–63. S8.1.2.5.2-10.	 Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:e783–831. S8.1.2.5.2-11.	 Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3:896–905. S8.1.2.5.2-12.	 Poon SS, Field M, Gupta D, et al. Surgical septal myectomy or alcohol septal ablation: which approach offers better outcomes for patients with hypertrophic obstructive cardiomyopathy? Interact Cardiovasc Thorac Surg. 2017;24:951–61. S8.1.2.5.2-13.	 Qin JX, Shiota T, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol. 2004;93:171–5. S8.1.2.5.2-14.	 Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129:351–8. S8.1.2.5.2-15.	 Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal

ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44:2329–32.

Downloaded from http://ahajournals.org by on October 7, 2026